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Abstract: Lenalidomide is a novel thalidomide analogue with enhanced immunomodula-
tory and antiangiogenic action lacking most of the typical thalidomide-associated adverse 
events. In myelodysplastic syndromes (MDS), it has been used primarily in the IPSS low- and 
intermediate-1 risk setting. Several trials have demonstrated its potential to lead to both erythroid 
and cytogenetic responses in these disease groups. In a clinical trial of patients with a del(5q) 
chromosomal abnormality, lenalidomide treatment resulted in red blood cell (RBC) transfusion 
independence in 67% of patients. Moreover, 45% of patients achieved a complete cytogenetic 
remission, and 28% achieved a minor cytogenetic remission. This result was independent of 
karyotype complexity. Lenalidomide might also induce long-term remissions in del(5q) patients 
with an elevated medullary blast count. In non-del(5q) patients, 43% of patients with conﬁ  rmed 
low- and intermediate-1 risk achieved transfusion independence or a reduction of at least 50% 
of pre-treatment RBC transfusion levels. Adverse events are common but manageable and 
include neutropenia and thrombocytopenia, pruritus, rash, diarrhea, and others. Lenalidomide 
will prove an essential part in the armamentarium of MDS therapeutics. Combination therapies 
with cytokines, demethylating agents, tyrosine kinase inhibitors, or chemotherapy are being 
investigated and may show additional beneﬁ  t in both low- and high risk MDS.
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Introduction
For many decades, the therapeutic approaches to myelodysplastic syndromes (MDS) 
have been a history of sorry failures. This was partly due to difﬁ  culties in diagnosis 
and prognostication, but also due to a poor understanding of the basic pathophysiol-
ogy of MDS. Recent years have shed light on most of these issues (Aul et al 1998), 
and, consequently, led to the identiﬁ  cation of possible cellular, immunological, and 
molecular therapeutic targets. Moreover, it has been recognized that the bone mar-
row microenvironment is not an innocent bystander in the malignant process, but 
may play a crucial role in the development and the support of neoplastic stem cells 
and their progeny (Estey 2004). Several lines of evidence support the view that the 
bone marrow stromal cells may be an independent target for therapeutic interven-
tions in myelodysplatic syndromes, as they seem not to be derived from a common 
hematopoietic malignant marrow stem cell (Ramakrishnan et al 2006). Our current 
understanding of the pathogenic mechanisms in MDS is that genetic alterations within 
hematopoietic stem cells might confer a growth advantage to them (Aul et al 1998; 
Fenaux 2001). These mutational events may be point mutations or loss or gain of 
chromosomal material, and may be found in the genome of the cellular nucleus or be 
conﬁ  ned to the mitochondrial DNA (Greenberg et al 2002). Furthermore, epigenetic 
alterations may lead to silencing of DNA sequences that interfere with normal pro-
liferation and differentiation (Lubbert 2003). The morphological correlates of these 
genetic abnormalities are dysplastic hematologic progenitors and effector cells in a Therapeutics and Clinical Risk Management 2007:3(4) 554
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hypercellular bone marrow of affected individuals (Schaefer 
and Lubbert 2005). Still, the disease is usually accompanied 
by peripheral pancytopenia. The paradox of bone marrow 
hypercellularity and peripheral cytopenia is explained by 
increased apoptosis in hematopoiesis that is partly due to an 
impaired responsiveness of progenitor cells to trophic signals 
and the generation of inhibitory cytokines by immune cells, 
bone marrow stroma, and malignant cells themselves (Aul 
et al 1998). At later stages of the disease, a shift from apopto-
sis to proliferation occurs (Parker and Mufti 1998) and about 
30% of patients’ bone marrows undergo evolution to acute 
myeloid leukemia (AML) (Heaney and Golde 1999).
Cytogenetic abnormalities in MDS
Abnormalities detected by conventional cytogenetics occur in 30 
to 50% of de novo MDS and in 80 to 90% of secondary MDS 
patients (Solé et al 2005). In contrast to acute myeloid leukemias, 
chromosomal aberrations in MDS usually involve loss or gain of 
chromosomal material, thus suggesting that the loss of tumor sup-
pressor genes or haploinsufﬁ  ciency of genes necessary for normal 
myelopoiesis play a critical role in pathogenesis (Olney and Le 
Beau 2001). A recent analysis of 2124 patients from several MDS 
centers shows that the most common cytogenetic abnormalities in 
myelodysplastic syndromes involve deletion of the long arm of 
chromosome 5 [del(5q)] in about 15% of patients, chromosomal 
aberrations of chromosome 7 (10% of abnormalities), trisomy 8 
(8% of cases), and complex karyotypes (13% of cases) (Haase 
et al 2005). Targeting speciﬁ  c chromosomal aberrations could 
therefore be of importance for a signiﬁ  cant number of patients 
suffering from MDS.
Therapeutic strategies in MDS
Currently, the therapeutic decisions for myelodysplastic 
syndromes are usually based on the International Prognostic 
Scoring System (IPSS) proposed by Greenberg and co-work-
ers (Greenberg et al 1997). This system includes number and 
degree of peripheral cytopenias, bone marrow blast count, and 
bone marrow cytogenetics to determine the overall survival 
and the probability of AML evolution in a given patient with 
MDS (Table 1). It is common clinical practice to group patients 
with low- and intermediate-1-risk- disease into one MDS risk 
category and intermediate-2 and high-risk patients into a higher 
risk group. If eligible, patients with high-risk MDS should 
undergo allogeneic bone marrow transplantation, because 
this treatment has shown a survival advantage over support-
ive care (Steensma and Bennett 2006). Patients with low-risk 
MDS (including IPSS low- and intermediate-1 risk) probably 
beneﬁ  t from a more conservative approach, leaving allogeneic 
stem cell transplantation for the time of clinical progression 
of the disease (Cutler et al 2004). Different treatment options 
are summarized in Table 2 (Bowen et al 2003, Bowen 2005, 
Steensma and Bennett 2006). Most of these treatments are 
appropriate for subsets of patients. Erythropoietin (EPO) with 
or without granulocyte colony stimulating factor (G-CSF) is 
most efﬁ  cacious in patients with low endogenous EPO levels 
and low red cell transfusion burden (Hellstrom-Lindberg 
et al 2003), while antithymocyte globulin and cyclosporine 
A seems to be promising in younger patients with a certain 
HLA subtype (DR B15) and hypoplastic MDS (Molldrem 
et al 2002). Epigenetic therapy with the demethylating agents 
azacitidine or decitabine may be used in patients with poor 
risk karyotypic abnormalities with int-1 disease (Lubbert and 
Wijermans 2005; Raj et al 2005). The immunomodulatory drug 
lenalidomide has yielded impressive results in the subset of 
red blood cell (RBC) transfusion dependent myelodysplastic 
syndromes with a del(5q) cytogenetic abnormaliy. The data 
of a phase II study led to its approval for this indication in 
December, 2005 (List et al 2005). Furthermore, lenalidomide 
Table 1 The international prognostic scoring system (IPSS) (Greenberg et al 1997)
       Points   
   0  0.5  1  1.5  2.0
BM blasts (%)    0–4  5–10    11–20  21–29
Number of cytopenias1   0–1  2–3     
Cytogenetic category2   low  int  high   
Risk group  Score       
Low 0       
Intermediate I  0.5–1       
Intermediate II  1.5–2       
High  ≥2.5      
1Neutrophils <1800/µl, platelets <100.000/µl, hemoglobin <10g/dl
2Good: normal, isolated del(5q), isolated del(20q), isolated –Y; poor: chromosome 7 abnormalities, complex abnormalities ( chromosomal abnormalities); intermediate: all 
others.Therapeutics and Clinical Risk Management 2007:3(4) 555
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has also been used in other low- and int-1-risk MDS leading 
to red cell transfusion independence in a signiﬁ  cant number 
of patients (Raza et al 2005).
Lenalidomide: a pleiotropic thalidomide 
analogue
Lenalidomide is chemically closely related to its parent 
compound, thalidomide (Bartlett et al 2004). However, the 
structural alterations between those compounds have as 
consequence pronounced differences in biological effects, 
the most striking, perhaps, being that lenalidomide is non-
teratogenic in the New Zealand rabbit preclinical model, 
which is the most sensitive animal model for thalidomide-
associated teratogenicity (Bartlett et al 2004) (Table 3). In 
preclinical and clinical tests, lenalidomide was shown to 
have a wide range of immunomodulatory, anti-inﬂ  ammatory, 
and antiangiogenic properties (Bartlett et al 2005). Angio-
genesis is a complex process involving interactions between 
endothelial cells, extracellular matrix, soluble factors, and 
their receptors (Estey 2004). Potent proangiogenic factors 
are vascular endothelial growth factor (VEGF) (Leung et al 
1989) and basic ﬁ  broblast growth factor (bFGF) (Crane and 
List 2005), the levels of which are signiﬁ  cantly reduced in the 
presence of lenalidomide (Bartlett et al 2004). Interestingly, 
VEGF is not only a powerful proangiogenic molecule but 
also directly stimulates leukemia cell self-renewal, as those 
cells may excrete VEGF and express VEGF-receptors (Estey 
2004). In del(5q) myelodysplastic syndromes, the levels of 
VEGF and its receptor KDR were signiﬁ  cantly reduced in 
all complete responders to lenalidomide, and vasculariza-
tion normalized, which proved to be a prognostic factor for 
remission induction and remission maintenance (Büsche 
et al 2005). In multiple myeloma, lenalidomide prevented 
growth by inhibiting plasma cell adhesion to bone marrow 
stromal cells (BMSCs) (Hideshima et al 2000). Adhesion 
of multiple myeloma cells to BMCSs triggers secretion of 
proangiogenic cytokines and further promotes angiogenesis 
(Bartlett et al 2004).
The anti-inflammatory effects of lenalidomide are 
based on its ability to reduce TNF-α production and 
inhibit Interleukin (IL)–6 and IL–1β-production, while 
enhancing IL–10, IL–2 and Interferon (IFN)-γ secretion 
(Corral et al 1999). Immune modulation was shown in both 
chronic viral infections, in animal models treated after Raji 
lymphoma cell inoculation, and in in-vitro models with anti-
CD3-stimulated CD4+ and CD8+ T-cells during peripheral 
blood mononuclear cell co-stimulation (Mitsiades and 
Mitsiades 2004).
Clinical use of thalidomide 
in myelodysplastic syndromes
There is no doubt that thalidomide is an active com-
pound in the treatment of myelodysplastic syndromes. 
A number of international study groups have investi-
gated on the safety and efficacy of thalidomide in both 
low- and high-risk MDS patients. Raza et al (Raza et al 
2001) treated 83 patients (36 refractory anemia, RA, 13 
patients with refractory anemia with ring sideroblasts, 
RARS, 24 refractory anemia with blast excess, RAEB, 
6 refractory anemia with blast excess in transformation, 
Table 2 Current treatment options in low- and intermediate-1 
risk myelodysplastic syndromes (not covering all experimental 
therapies)
•  Blood transfusion (erythrocytes, platelets)
•  Iron chelation therapy (deferasirox, deferoxamine, deferiprone)
• Danazol
• Pyridoxine
•  Erythropoietin ± granulocyte colony-stimulating factor
• Valproic  acid




• Low-dose  cytarabine
Table 3 Comparison of clinical, biological, and molecular fea-
tures between thalidomide and lenalidomide 
 Thalidomide  Lenalidomide
Teratogenicity (animal   +  –
model)  
Inhibition of cytokine   +  +++
generation (TNF-α, IL-6)   
Stimulation of IL-10, IL-2,   +  +++
IFN-γ  
Antiangiogenesis + ++
Adverse events   
Constipation ++  –
Polyneuropathy ++  –
Sedative effects  +++  –
Deep venous thrombosis  +  (+)*
T-cell costimulatory effect  +  ++
Enhancement of NK-cell   +  +
Cytotoxicity  
Reduction in tumor growth in   +  ++
Vivo (SCID mice)   
Abbreviation: NK, natural killer; IL, Interleukin; TNF, tumor necrosis factor; IFN, 
Interferon; SCID, severe combined immunodeﬁ  ciency. 
* DVT not a clinical problem in myelodysplastic syndromes, but important in 
multiple myeloma.Therapeutics and Clinical Risk Management 2007:3(4) 556
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RAEB-t, and 4 patients with chronic myelomonocytic 
leukemia, CMML) at a median age of 67 years with 
doses ranging from 100 to 400 mg thalidomide per day. 
Only 8 patients took the maximum dose of 400 mg tha-
lidomide throughout the study. The majority of patients 
did not tolerate higher doses than 150 to 200 mg once 
daily. 51 patients completed at least 12 weeks of therapy, 
the remaining 32 patients stopped study drug early due 
to adverse events or progressive disease. 16 out of 51 
patients (31%) showed hematologic improvement, with 
10 out of 51 patients (20%) achieving major responses 
according to IWG criteria (Cheson et al 2000), ie, transfu-
sion independence in previously transfusion dependent 
patients. Median duration of responses was 306 days 
(range, 90–620). Interestingly, most of the responders 
belonged to the low- and intermediate-1-risk IPSS group 
(9 RA and 5 RARS). Responders had a significantly 
higher pretherapy platelet count than non-responders and 
a lower pretreatment transfusion dependence for platelets. 
No cytogenetic remissions were observed in this study, 
however, Strupp et al reported three cytogenetic responses 
out of 16 MDS patients with chromosomal abnormalities 
treated with thalidomide (Strupp et al 2003). Two of the 
three patients were poor risk karyotypes (RA, 45, XY, 
–7, and RAEBt, complex karyotype), but most impor-
tantly, two of these patients had involvement of the long 
arm of chromosome 5; one as a single abnormality (RA, 
46, XX, del(5)(q22q33), and one as part of a complex 
karyotypic abnormality [RAEBt, 46, XY, del(2)(p13?4), 
del(5)(q13q33), add(17)(p11), del(20)(q11)]. These pa-
tients were included in a report of a trial of 53 patients 
with MDS treated with thalidomide for myelodysplastic 
syndromes: 22 RA, 9 RARS, 6 RAEB, 12 RAEBt, 4 
CMML, median age 66 years. Median thalidomide dosage 
was 300 mg. 22 out of 53 patients discontinued thalido-
mide because of adverse events. The overall response 
rate according to IWG criteria was 26 out of 53 patients, 
ie, 49% at a median follow-up of 12 months (range, 12 
to 25 months) (Musto 2004).
Two other studies conﬁ  rmed the activity of thalidomide 
in MDS patients, with overall responses ranging from 20 to 
38 % (Musto 2004).
Clinical use of lenalidomide 
in myelodysplastic syndromes
Given the successful clinical use of thalidomide in myelo-
dysplastic syndromes and the fact that lenalidomide has sig-
niﬁ  cantly stronger antiangiogenic and anticytokine properties 
than the parent compound, clinical trials investigating the 
potential of this immunomodulatory drug (IMiD®) in the 
treatment of MDS have consequently been designed. The 
trials focused mainly on transfusion-dependent low- and 
intermediate-1 risk MDS populations, although clinical tri-
als in high-risk MDS and AML patients are also currently 
being performed.
Lenalidomide (CC5013)-MDS-001 trial
In the Lenalidomide- MDS-001 trial, List and co-workers 
treated 43 patients with MDS and transfusion-depen-
dent or symptomatic anemia with varying doses of oral 
lenalidomide, ranging from 25 mg every day to 10 mg 
daily to 10 mg for 21 days of every 28 days cycle (List 
et al 2005). All patients had had no response to erythro-
poietin therapy or had high endogenous erythropoietin 
level with low probability of benefit to such therapy. 
Responses were defined according to the modified IWG 
criteria (Cheson et al 2000). A major erythroid response 
was defined as freedom from transfusion or an increase in 
hemoglobin levels of more than 2 g/dl in previously trans-
fusion dependent patients. A major cytogenetic response 
was defined by the absence of the prestudy cytogenetic 
abnormality in at least 20 metaphases, a minor response 
by a reduction of at least 50% in the number of abnormal 
metaphases. 43 patients were included with a median 
age of 72 years (range, 28–85). 20 patients (47%) had 
RA, 13 patients (30%) RARS, 8 patients RAEB (19%), 
1 patient RAEBt (2%), and 1 patient CMML (2%). 88% 
of patients had low- or int-1 risk IPSS risk assessment. 
74% of patients were transfusion dependent with a me-
dian transfusion requirement of 3 packed red cells every 
4 weeks. 53% of patients had an abnormal karyotype, 
47% had no chromosomal abnormalities.
Lenalidomide-MDS-001 trial – Patient sample 
at a glance
•  About 75% of patients heavily transfusion dependent. 
•  Representative study population regarding age and
  sex distribution of patients.
•  88% of patients low- or intermediate-1 risk according
 to  IPSS.
•  Abnormal karyotypes in about 50% (Table 4). 
Fiftysix percent of patients (n = 24) had a response to 
lenalidomide treatment. 63% of transfusion-dependent 
patients (20 out of 32) achieved transfusion independence. 
The median hemoglobin increase in major responders (ie, 
reaching transfusion independence or >2 g/dl increase in Therapeutics and Clinical Risk Management 2007:3(4) 557
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hemoglobin) was 5.3 g/dl. 1 out of 10 patients with moderate 
to severe thrombocytopenia had a sustained platelet count 
increase, 2 out of 12 patients with severe neutropenia had a 
sustained neutrophil increase. The only signiﬁ  cant predic-
tive factor for response was the karyotypic abnormality at 
treatment onset. 83% of patients with a del(5q31) MDS had 
a response as compared to 53% of patients with a normal 
karyotype and 12% of patients with other karyotypic abnor-
malities (Table 5). The most common adverse events were 
neutropenia and thrombocytopenia and necessitated dose 
interruption or dose reduction in 58% of patients, and this 
was dose dependent (77% in the 25 mg group, 62% in the 
10 mg daily group, and 47% in the 10 mg 3 weeks out of 4 
group, see Table 6). Other adverse events, albeit not usually 
of grade 3 and 4 according to National Cancer Institute (NCI) 
were pruritus, urticaria and skin rash, diarrhea, hypothyroid-
ism and hypogonadism.
Four patients had transient emergence of karyotypically un-
related clones. Sustained acquisition of chromosomal aberrations 
occurred in four patients. Three del(5q31) patients developed 
chromosome 7 abnormalities and one patient with a normal 
pre-treatment karyotype developed del(20q). One of these four 
patients had exacerbation of anemia at the time of emergence of 
chromosomal abnormality. This patient transformed into acute 
leukemia. The other patients remained transfusion free.
Conclusion of the Lenalidomide- 
MDS- 001 trial
This trial clearly showed the potential of lenalidomide in 
the treatment of myelodysplastic syndromes. Patients with a 
del(5q31) chromosomal aberration appeared to be responding 
especially well to treatment. Neutropenia and thrombocy-
topenia were common side effects. Thrombocytopenia is 
a less important clinical problem, though. 54% of patients 
experienced grade 3 or 4 thrombocytopenia, but grade 4 is 
the clinical important problem (platelets <25,000/µl), while 
grade 3 does not usually lead to spontaneous bleeding. 
The typical adverse events reported with thalidomide (eg, 
constipation, fatigue, polyneuropathy) were uncommon 
or non-existent. The signiﬁ  cance of sustained acquisition 
of chromosomal abnormalities is unclear, three out of four 
patients with emergence of new clones were sustained 
responders to the drug.
Given that the MDS-001 trial had shown different efﬁ  cacy 
in MDS patients with del(5q31) cytogenetic abnormality and 
non-del(5q) MDS, two further trials were designed to study 
the effects of lenalidomide in more depth in those study 
populations. The MDS 003 trial was designed for transfu-
sion dependent del(5q) MDS patients, the MDS 002 trial for 
patients with other or no chromosomal abnormalities.
Lenalidomide (CC5013)-MDS-002 trial 
(Raza et al 2005)
In this clinical phase II study, transfusion-dependent MDS 
patients needing at least 2 RBC concentrates every 8 weeks 
were included. Patients were eligible if they had low- or 
intermediate-1 risk MDS without any or with non-del(5q) 
chromosomal abnormalities. Because of the myelosuppressive 
effect demonstrated by lenalidomide the patients were to have 
50,000/µl platelets and an absolute neutrophil count (ANC) 
of 500/µl. The primary endpoint of the study was transfu-
sion independence; secondary endpoints included cytogenetic 
and pathologic response to lenalidomide. This trial has not yet 
been published as a full paper, which limits the deﬁ  nite data 
Table 5 Predictive factors for lenalidomide response at a glance 
(Lenalidomide-MDS-001 trial, total number of patients, n=43) 
(List et al 2005)
Variable  No. of   Erythroid   P-value
 patients  response  (%)
IPSS risk group      0.14
Low 22  15  (68) 
Intermediate-1 16  8  (50) 
Intermediate 2 or high  5  1 (20) 
FAB classiﬁ  cation      0.07
RA 20  15  (75) 
RARS 13  6  (46) 
RAEB(t) 9  3  (33) 
CMML 1  0 
Karyotype     0.007
del(5q31) 12  10  (83) 
Normal 23  13  (57) 
Other 8  1  (12) 
Table 4 Lenalidomide-MDS-001 trial – Chromosomal abnor-
malities and responses at a glance (List et al 2005)
Cytogenetic  No. of patients  Complete cyto 
abnormality   genetic  responses
del(5q31.1) 12  9(75%) 
isolated 11  8 
with trisomy 21  1  1
del(20)(q11.2) 2  0
T(1;22)(q21p11.2) 1  1
Other* 5  0
Total 20  10(50%)
*+19; +8; –X; t(3;3) (q21; q26.3); and complexTherapeutics and Clinical Risk Management 2007:3(4) 558
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analysis. 215 patients at a median age of 71 years were included 
in this trial. 77% of evaluable patients had a normal karyo-
type, 23% displayed chromosomal abnormalities. Low- and 
intermediate-1 risk MDS was conﬁ  rmed in 79% of patients. 
Average duration of MDS was 2.7 years (range, 0.1–12.9 
years). In the intent-to-treat analysis including all 215 patients 
regardless of central review eligibility, 21.4% were identiﬁ  ed 
as transfusion independent with a median haemoglobin rise 
of 3.0 g/dl. Among 79% low- and intermediate-1 patients 
25% became transfusion independent, while a total of 43% 
achieved a major or minor response (Table 7). The median 
time to transfusion independence was 4.2 weeks. The duration 
of response was at least 24 weeks in 17% of responders and 
was at least 52 weeks in 10% of the patients. As in the MDS 
001 trial, the most common adverse events were neutropenia 
and thrombocytopenia (Table 8). These adverse events neces-
sitated treatment interruption in 19% and 15%, respectively. 
Possible drug related deaths were reported in 2% of patients. 
Those were due to neutropenic infections.
Lenalidomide-MDS-002 trial – Patient sample 
at a glance
•  Representative MDS study population regarding age
  and sex distribution of patients.
•  80% of patients low- or intermediate-1 risk according
 to  IPSS.
•  Normal karyotypes in 77%.
Conclusion of the Lenalidomide- 
MDS-002 trial
Lenalidomide unequivocally has erythroid remitting activ-
ity in myelodysplastic syndromes, not only in the del(5q) 
population but also in patients with normal or other abnor-
mal karyotypes. Neutropenia and thrombocytopenia were 
the most common side effects, however, in the non-del(5q) 
population these adverse events are about half as frequent 
as in del(5q) MDS patients. The study shows a 43% overall 
erythroid response rate in the low- and intermediate-1 risk 
patients. This included minor erythroid responses with a 50% 
reduction in transfusion requirements compared to baseline, 
which is a rather weak response criterion. However, 25% of 
patients achieved transfusion independence with a median 
hemoglobin rise of 3.0 g/dl, comparing favorably to many 
other therapies in this indication. This trial included 77% 
of patients with a normal karyotype. Additional studies are 
needed in non-del(5q) patients with other karyotypic abnor-
malities to assess lenalidomide’s ability to induce erythroid 
responses in these patient subgroups.
Lenalidomide MDS-003-trial
The very impressive results of the Lenalidomide-MDS-001 
trial prompted the design of an international phase II trial for 
patients with a del(5q) chromosomal abnormality, the results 
of which have recently been reported in the New England 
Journal of Medicine (List et al 2006). The study population 
consisted of 148 transfusion-dependent patients (>2 RBC/ 8 
weeks, median RBC transfusion burden 6 Units/8 weeks) with 
a median age of 71 years and a female preponderance typical 
of the 5q-syndrome. Mean MDS duration at study enrolment 
was 3.4 years (<0.1 to 20.7). The patient population consisted 
of transfusion-dependent low- and intermediate-1-risk MDS 
patients according to IPSS with a del(5q) cytogenetic abnor-
mality including bands q31–q33, allowing for the inclusion 
of patients with del(5q) chromosomal abnormalities plus one 
or more other cytogenetic aberrations, as well as patients with 
a medullary blast count of >5%. It is important to recognize 
that these different patient populations, although sharing 
the del(5q) chromosomal abnormality, have a very different 
overall survival. In fact, while patients with an isolated del(5q) 
aberration and a normal bone marrow blast count (the 5q-
syndrome) have a median overall survival exceeding 6 years 
(Giagounidis et al 2004), this ﬁ  gure shrinks to 48 months for 
patients with one additional chromosomal aberration (eg, 
del(5q) +21), and more so for patients with complex karyo-
Table 7 Responses in Lenalidomide-MDS-002 trial (Raza et al 
2005)
Intent to treat (n = 215)  No. of patients (%)
Transfusion Independence  21.4%
Low-/Intermediate-1 patients (n = 169) 
Transfusion Independence  25%
Minor response   18%
(>50% reduction of transfusion requirements) 
Total 43%
Table 6 Hematological adverse events at a glance (Lenalidomide-001-trial, total number of patients, n = 43) (List et al 2005)
  Grade 1 or 2 (NCI)  Grade 3 or 4 (NCI)  All patients, all grades
Neutropenia  0  28 (65%)  28 (65%)
Thrombocytopenia  9 (21%)  23 (53%)  32 (74%)Therapeutics and Clinical Risk Management 2007:3(4) 559
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types including del(5q) (median overall survival 7–8 months 
(Giagounidis et al 2005)). An increase in bone marrow blasts 
in patients with an isolated del(5q) abnormality also confers a 
worse prognosis compared to the 5q-syndrome, those patients 
having a median overall survival of about 2 years (Giagouni-
dis et al 2004). By choosing the above-mentioned inclusion 
criteria, the Lenalidomide-MDS-003 trial was able to address 
the question of whether this compound was able to act not 
only on the 5q-syndrome population, but also on higher-risk 
disease subgroups.
Lenalidomide-MDS-003 trial – Patient sample 
at a glance
•  Transfusion-dependent del(5q) MDS patients of
  low-and intermediate-1 IPSS risk. 
•  Representative del(5q) study population regarding
  age and sex distribution of patients. 
•  Additional karyotypic abnormalities allowed. 
•  Increased medullary blast count up to 10% allowed
  if isolated del(5q). 
•  Platelet count >50,000/µl and ANC >500/µl required.
Primary endpoints in this trial, as in the MDS 002 trial, 
were transfusion independence, secondary end points were 
cytogenetic and pathological response. To be classiﬁ  ed as a 
major response, transfusion independence had to last for at 
least 8 weeks and be accompanied by a rise in hemoglobin 
of at least 1 g/dl. Lenalidomide was given at 10 mg/day with 
possible dose reductions in case of adverse events to 5 mg p.o. 
daily and 5 mg p.o. daily every other day. Response according 
to modiﬁ  ed IWG criteria (Cheson et al 2000) was assessed 
after 24 weeks. Among 148 included patients, 111 had a 
single del(5q) chromosomal abnormality, and 37 patients 
had additional chromosomal abnormalities. Central cytology 
and cytogentic review was performed and 120 patients (81%) 
conﬁ  rmed as suffering from low/ intermediate-1 risk MDS. 
The intent-to-treat analysis showed that 67% of patients 
(95% conﬁ  dence interval 59%–74%) became transfusion 
free, deﬁ  ned as 56 days of transfusion independence and   
a 1 g/dl rise in hemoglobin (Table 9). The median increase 
in hemoglobin from baseline to the maximum hemoglobin 
achieved during RBC transfusion independence was 5.4 g/dl 
and the median interval to response was 4.6 weeks. 90% 
of patients who achieved a transfusion beneﬁ  t did so by 
completion of three months in the study. RBC transfusion 
independence were unaffected by age, gender, FAB type, 
IPSS category or cytogenetic pattern. However, the patient 
numbers in intermediate-2 and high risk IPSS were very 
low (6 and 2, respectively). With a median follow-up of 104 
weeks, the median duration of transfusion-independence was 
not reached. Although patients with isolated del(5q) were 
more likely to achieve transfusion independence (72%), 48% 
of patients with one additional chromosomal abnormality and 
67% of those with 2 or more additional abnormalities did also 
achieve freedom from transfusion. 73% of patients achieved 
a cytogenetic response: 45% had a complete cytogenetic 
remission with absence of the del(5q) cytogenetic abnormal-
ity in follow-up karyotyping, and 28% had a reduction of 
at least 50% in abnormal metaphases (Table 9). 23 patients 
acquired new chromosomal abnormalities during lenalido-
mide treatment, 10 of whom were cytogenetic responders. 
84% of patients had to interrupt the dose of lenalidomide 
due to adverse events at least once. The median time to the 
ﬁ  rst dose interruption or reduction was 22 days. The median 
duration of the ﬁ  rst interruption was 22 days. A second dose 
reduction or interruption was necessary in 33.8% of patients. 
This second interruption had a median duration of 21 days. 
Grade 3 or 4 neutropenia developed in 55% of patients, grade 
3 or 4 thrombocytopenia in 44% (Table 10). Nine patients 
progressed to higher MDS subtypes or acute myeloid leu-
kemia, and 11 patients died due to disease complications 
(n = 8) or neutropenic infection (n = 3).
Conclusion of the Lenalidomide- 
MDS-003 trial
Lenalidomide is a highly effective treatment for patients with 
a del(5q) myelodysplastic syndrome. 67% of patients in this 
trial became transfusion independent with a median hae-
Table 8 Hematological adverse events leading to treatment 
interruption in the Lenalidomide-MDS-002-trial (Total number of 
patients, n = 215) (Raza et al 2005)
  All patients, all grades
Neutropenia 19%
Thrombocytopenia 15%
Table 9 Lenalidomide-MDS-003: Erythroid and cytogenetic 
response rates (List et al 2006)
Intent to treat (n = 148)  No. of patients (%)
Transfusion Independence  99 (67%)
>50% reduction of transfusion need   13 (9%)
(but not transfusion-free) 
Median haemoglobin increase  5.4 g/dl
Median interval to response  4.6 weeks
Overall cytogenetic response  73%
Complete cytogenetic response  45%Therapeutics and Clinical Risk Management 2007:3(4) 560
Giagounidis et al
moglobin rise of 5.4 g/dl. The median duration of response 
has not been reached at the latest data cut-off. Importantly, 
the drug’s cytogenetic remitting activity is not conﬁ  ned to 
patients with isolated del(5q), but also occurs in patients 
with additional chromosomal abnormalities. Neutropenia 
and thrombocytopenia are the most common side effects, 
occurring in 55% and 44% of patients.
Conclusion and future perspectives
It may turn out to be a fortunate event that thalidomide, a 
sedative once developed by Chemie Grünenthal in Germany in 
the 1950s, did not disappear completely from the pharmaceu-
tical market after the shocking and traumatizing teratogenic 
effects that struck thousands of families during the early 
years of its marketing. Indeed, it seems to be by complete 
chance that the beneﬁ  cial effects of thalidomide on Erythema 
nodosum leprosum were discovered by Jacob Sheskin in 
1965 (Sheskin 1965). More than thirty years later, chance 
again led to the discovery of thalidomide’s positive action 
in multiple myeloma (Singhal et al 1999). Since, extensive 
research has discovered a number of thalidomide analogues 
with augmented immunomodulatory and anti-cytokine effects 
that may lead to important steps forward in the treatment of 
neoplastic diseases. In multiple myeloma and in the myelo-
dysplastic syndromes, this has already been achieved by one 
of those new compounds, namely CC5013, or lenalidomide. 
In MDS, past and current trials have unequivocally shown 
that this drug has a potential to alleviate transfusion depen-
dence in all subgroups of MDS. It seems to be particularly 
effective in patients with a del(5q) chromosomal abnormality 
when the bands q31 to q33 are involved. Here, this drug has 
shown to achieve transfusion independence in the majority 
of patients with isolated del(5q) or additional chromosomal 
abnormalities. The MDS-002 and 003 trials were designed 
to study low- and intermediate-1 patients. This led to the 
opportunity to study whether the drug is able to reduce a sig-
niﬁ  cantly elevated blast count, too. It turns out that lenalido-
mide not only may restore a normal erythropoiesis in del(5q) 
patients, but that it may also decrease an elevated blast count 
to normal ranges. It is at present unclear whether treatment 
with lenalidomide alone is sufﬁ  cient to induce long-term 
remissions in patients with elevated blasts or whether some 
form of combination treatment may be necessary to provide 
sustained response. In those patients with a del(5q) and a 
normal medullary blast percentage, however, it is clear that 
monotherapy with lenalidomide may lead to long-term trans-
fusion independence for at least several years. Furthermore, 
among patients with a del(5q) chromosomal aberration, those 
with two or more chromosomal aberrations, ie, a complex 
karyotype, undoubtedly do have an ominous prognosis (Gia-
gounidis et al 2005). Lenalidomide is able to induce long term 
hematologic and cytogenetic remissions in these patients with 
low- and intermediate-1 IPSS risk (Giagounidis et al 2006, 
Giagounidis et al 2005) and very probably alters the natural 
course of the disease in this patient population. Whether, in 
analogy, this is also true for patients with isolated del(5q) 
or with one additional karyotypic abnormality is unclear 
at the moment. The drug deﬁ  nitely improves quality of life 
in responding patients. Patients not responding to the drug 
during active treatment periods may experience a sustained 
rise in hemoglobin after drug discontinuation (Giagounidis 
et al 2006). Also, in our experience, patients interrupting 
treatment after short courses of lenalidomide (4–6 weeks) 
may experience prolonged transfusion independence of >18 
months (Giagounidis et al 2006). A number of patients will 
lose their response to the drug during active treatment. Some 
of these patients may be salvaged with readministration of the 
initial dose of lenalidomide (10 mg) after a drug holiday of 
4 weeks to 6 months. It has become clear that del(5q) patients 
are especially prone to hematologic toxicity after lenalidomide 
administration. To prevent neutropenia, granulocyte colony-
stimulating factors should be administered early at onset of 
neutropenia. Especially during the ﬁ  rst 8 weeks of treatment, 
full blood counts must be checked weekly to avoid serious 
hematologic side effects and possibly lethal complications 
of neutropenia. If the drug is interrupted at 30–50.000/µl 
platelets, the probability of severe bleeding is minimal, and 
never happened in our personal experience. The question has 
arisen whether it would be feasible to treat patients through the 
neutropenia and thrombocytopenia with vigorous supportive 
care, hoping to achieve higher response rates by administering 
a higher cumulated lenalidomide dose. However, given that 
patients with low- and intermediate-1 risk disease according 
to the IPSS have median survival rates of 3.5 to >5 years, and 
that the survival of 5q-syndrome patients does exceed those 
ﬁ  gures, ethical considerations have led to a reluctance regard-
ing this approach. As long as more mature data from clinical 
trials are missing, we feel that treatment interruption should be 
Table 10 Lenalidomide-MDS-003: Overview on hematological 
adverse events (List et al 2006)
Intent to treat (n = 148)  No. of patients (%)
Neutropenia (Grade 3 or 4)  55%
Thrombocytopenia (Grade 3 or 4)  44%
Median duration of treatment interruptions  3 weeksTherapeutics and Clinical Risk Management 2007:3(4) 561
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performed according to the guidelines outlined in the studies 
reported on. Lenalidomide is a thalidomide analogue. Every 
precaution must be taken to prevent pregnancies during and 
for at least one month after lenalidomide intake.
Whether the combination of erythropoietin and lenalido-
mide will be able to improve overall responses is uncertain. 
Given that erythropoietin levels in del(5q) patients are 
usually very high at the time of diagnosis (Giagounidis 
et al 2004), it is improbable that a combination therapy will 
improve responses signiﬁ  cantly. Also, the drug’s potential in 
advanced MDS or AML with del(5q) requires further stud-
ies. Firstly, those diseases may have a different genetic basis 
than low-risk MDS with del(5q) because the critical deleted 
region on chromosome 5 is likely to be different (Boultwood 
et al 2002). Secondly, although lenalidomide in vitro has got 
a direct apoptotic effect on del(5q) cells, its action is usually 
considered more from an immunomodulatory, anti-cytokine, 
and bone marrow microenvironment balancing view. In 
this case it is improbable that lenalidomide alone will cure 
patients with an elevated blast count >10%, but it may be 
an important adjunct to other drugs, including conventional 
chemotherapy, demethylating agents, farnesyl transferase 
inhibitors, tyrosine kinase inhibitors, and others.
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